Clinical Trial Update: Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and feasibility of a liposomal cytarabine, daunorubicin, and gemtuzumab ozogamicin combination in relapsed/refractory pedi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Daunorubicin (daunorubicin)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)
• Liposomal cytarabine (cytarabine liposome)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED